Merck-Moderna Personalized mRNA Vaccine Reduces Melanoma Recurrence Risk by 42 Percent in Phase 2 Trial
Phase 2 data show the personalized mRNA vaccine intismeran plus Keytruda cut melanoma recurrence risk 42 percent versus Keytruda alone. The approach builds on COVID-era mRNA technology but faces manufacturing, cost, and durability hurdles. Phase 3 results and regulatory decisions will determine expansion to other cancers.
Next milestones include full peer-reviewed publication of the ESMO dataset and FDA breakthrough designation review. If phase 3 confirms hazard ratios below 0.70 at three-year follow-up, regulatory approval for resected melanoma could occur by late 2026, enabling rapid expansion to other solid tumors via basket designs.
VITALIS: Phase 3 melanoma data will show hazard ratio below 0.65 for recurrence-free survival at 36 months if enrollment completes by mid-2025.
Sources (3)
- [1]STAT News on ESMO 2024 intismeran results(https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/)
- [2]Moderna phase 2b melanoma trial abstract ESMO 2024(https://www.esmo.org/meetings/esmo-congress-2024)
- [3]NEJM mRNA-4157 plus pembrolizumab melanoma update(https://www.nejm.org/doi/full/10.1056/NEJMoa2305771)